The role of a clinical pharmacist in implementing modern guidelines for the pharmacotherapy of arterial hypertension

Authors

DOI:

https://doi.org/10.24959/sphhcj.23.303

Keywords:

the role of a clinical pharmacist; arterial hypertension; hypertension management; fixed combinations.

Abstract

Aim. To study the possibilities of participation of a clinical pharmacist in complying with modern guidelines for antihypertensive pharmacotherapy using fixed combinations of drugs in the conditions of a pharmacy and determine the directions for improving the work of a clinical pharmacist to improve the quality of hypertension control.

Materials and methods. The analysis of reports on the sale of antihypertensive drugs containing one active substance and fixed combinations of two or three active substances was carried out in a pharmacy at a healthcare institution.

Results. Sales volumes of combined drugs prevailed over sales volumes of drugs that contained one active substance, and fixed combinations of two active substances prevailed over triple combinations. However, the frequency of selling two drugs of different groups as separate drugs was higher than the sale of drugs of two or three pharmacological groups as fixed combinations. At the same time, sales of fixed combinations prevailed for individual active substances among the angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

Conclusions. Data on the sale of fixed combinations of two or three active substances in the pharmacy have demonstrated insufficient compliance with current guidelines for antihypertensive pharmacotherapy. One of the ways to improve compliance with modern guidelines for the use of fixed combinations is the active participation of the clinical pharmacist in the selection of drugs for a particular patient, actively interacting with the doctor. Thus, a clinical pharmacist can be an important link in the control of arterial hypertension and the implementation of modern guidelines for the pharmacotherapy of arterial hypertension.

References

Dziuba, O. M., Pazynych, L. M., Sytenko, O. R., Kryvenko, Ye. M. (2017). Shchodo pytannia hlobalnoho tiaharia khvorob v Ukraini [Regarding the issue of the global epidemic of diseases in Ukraine]. Visnyk sotsialnoi hihiieny ta orhanizatsii okhorony zdorovia Ukrainy – Bulletin of social hygiene and health care organizations of Ukraine, 2 (72), 8-13. doi: 10.11603/1681-2786.2017.2.8101.

Diachuk, D. D, Moroz, H. Z., Hidzynska, I. M., Lasytsia, T. S. (2018). Poshyrenist faktoriv ryzyku sertsevo-sudynnykh zakhvoriuvan v Ukraini: suchasnyi pohliad na problemu [Prevalence of cardiovascular disease risk factors in Ukraine: a modern view of the problem]. Ukrainskyi kardiolohichnyi zhurnal – Ukrainian Journal of Cardiology, 1, 91-101. Available at: http://nbuv.gov.ua/UJRN/Ukzh_2018_1_12.

Arterialna hipertenziia. Klinichna nastanova. (2019). Available at: https://dec.gov.ua/wp-content/uploads/2019/11/kn_artergipert.

Soubra, L., & Elba, G. (2023). Pharmacist Role in Hypertension Management in the Community Setting: Questionnaire Development, Validation, and Application. Patient Prefer Adherence, 17, 351-367. doi: 10.2147/PPA.S394855.

Rahman, M. S. (2019). Hypertension: The Role of the Practice Pharmacist. Medscape UK. Retrieved 26 July 2019. Available at: https://www.medscape.co.uk/viewarticle/hypertension-role-practice-pharmacist-2022a10010o1.

Di Palo, K. E., Kish, T. (2018). The role of the pharmacist in hypertension management. Curr. Opin. Cardiol., 33 (4), 382-387. doi: 10.1097/HCO.0000000000000527.

Thompson, H., Swander, L., Cohen, R., Lukazewski, A., Bartholow, T., Pesik et al. (2020). Hypertension-focused medication therapy management: a collaborative pilot program uniting pharmacists, public health, and health insurers in Wisconsin. Prev. Chronic Dis., 17. doi: 10.5888/pcd17.200058.

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et al. (2018). ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 36 (10), 1953-2041. doi: 10.1097/HJH.0000000000001940.

Unger, T., Borghi, C., Charchar, F., Khan, N., Poulter, N., Prabhakaran, D. et al. (2020). International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75 (6), 1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.

Likuvannia arterialnoi hipertenzii: maibutnie – za fiksovanymy kombinatsiiamy. (2019). Apteka, 36. Available at: https://www.apteka.ua/article/515181.

Downloads

Published

2023-11-17

Issue

Vol. 9 No. 4 (2023)

Section

Health organization

License

Copyright (c) 2024 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).